Keishibukuryogan (Gui-Zhi-Fu-Ling-Wan), a Kampo formula, decreases disease activity and soluble vascular adhesion molecule-1 in patients with rheumatoid arthritis

Evidence-based Complementary and Alternative Medicine

Volumn 3, Issue 3, 2006, Pages 359-364

  Nozaki, Kazuya ^a   Hikiami, Hiroaki ^a   Goto, Hirozo ^a   Nakagawa, Takako ^a   Shibahara, Naotoshi ^a   Shimada, Yutaka ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Antioxidant; Lipid peroxide; Vascular cell adhesion molecule 1

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; KAMPO; KEISHI BUKURYO GAN; LIPID PEROXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; JOINT SWELLING; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 33748158340     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nel025     Document Type: Article

References (40)

1. Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Isomäki H. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995;13:149-53.
2. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
3. del Rincón I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
4. Wållberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapää-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002;29:875-82.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
6. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999;107:85-97.
7. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003;170:191-203.
8. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, et al. The expression of the adhesion molecules ICAM-1, VACM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993;171:223-9.
9. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerosis plaques: implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest 1993;92:945-51.
10. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996;93:672-82.
11. Mojcik CF, Shevach EM. Adhesion molecules: a rheumatologic perspective. Arthritis Rheum 1997;40:991-1004.
12. Tokuhira M, Hosaka S, Volin MV, Hainess GK, Katschke KJ, Kim S, et al. Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 2000;43:1122-33.
13. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 2002;61:804-9.
14. Klimiuk PA, Sierakowski S, Domystawska I, Fiedorczyk M, Chwiecko J. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp 2004;52:36-42.
15. Terasawa K. Evidence-based reconstruction of Kampo medicine: part I - is Kampo CAM? Evid Based Complement Alternat Med 2004;1:11-6.
16. Terasawa K. Evidence-based reconstruction of Kampo medicine: part II - the concept of Sho. Evid Based Complement Alternat Med 2004;1:119-23.
17. Terasawa K. Evidence-based reconstruction of Kampo medicine: part III - how should Kampo be evaluated? Evid Based Complement Alternat Med 2004;1:219-22.
18. Hikiami H, Goto H, Sekiya N, Hattori N, Sakakibara I, Shimada Y, et al. Comparative efficacy of Keishi-bukuryo-gan and pentoxifylline on RBC deformability in patients with "oketsu" syndrome. Phytomedicine 2003;10:459-66.
19. Sekiya N, Tanaka N, Itoh T, Shimada Y, Goto H, Terasawa K. Keishi-bukuryo-gan prevents the progression of atherosclerosis in cholesterol-fed rabbit. Phytother Res 1999;13:192-6.
20. Sekiya N, Goto H, Tazawa K, Oida S, Shimada Y, Terasawa K. Keishi-bukuryo-gan preserves the endothelium dependent relaxation of thoracic aorta in cholesterol-fed rabbit by limiting superoxide generation. Phytother Res 2002;16:524-8.
21. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
23. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
24. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:634-43.
25. Öztürk HS, Çimen MY, Çimen ÖB, Ka̧cmaz M, Durak Î. Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 1999;19:35-7.
26. Kamanli A, Naziroglu M, Aydilek N, Hacievliyagil C. Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochem Funct 2004;22:53-7.
27. Edmonds SE, Winyard PG, Guo R, Kidd B, Merry P, Langrish-Smith A, et al. Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis: results of a prospective placebo controlled double blind trial. Ann Rheum Dis 1997;56:649-55.
28. Helmy M, Shohayeb M, Helmy MH, el-Bassiouni EA. Antioxidants as adjuvant therapy in rheumatoid disease: a preliminary study. Arzneim Forsch Drug Res 2001;51:293-8.
29. Osborn L, Hession C, Tizard R, Vassallo C, Luhowskyj S, Chi-Rosso G, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59:1203-11.
30. Desideri G, Marinucci MC, Tomassoni G, Masci PG, Santucci A, Ferri C. Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increases nitric oxide concentrations in hypercholesterolemic patients. J Clin Endocrinol Metab 2002;87:2940-5.
31. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255-62.
32. De Caterina R, Basta G, Lazzerini G, Dell'Omo G, Petrucci R, Morale M, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2646-54.
33. Desideri G, Croce G, Tucci M, Passacquale G, Broccoletti S, Valeri L, et al. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J Clin Endocrinol Metab 2003;88:5341-7.
34. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-42.
35. Kasahara Y, Goto H, Shimada Y, Sekiya N, Yang Q, Terasawa K. Effects of Keishi-bukuryo-gan (Gui-Zhi-Fu-Ling-Wan) on endothelial function in spontaneously hypertensive rats. J Trad Med 2001;18:113-8.
36. Goto H, Shimada Y, Sekiya N, Yang Q, Kogure T, Mantani N, et al. Effects of Keishi-bukuryo-gan on vascular function and hemorheological factors in spontaneously diabetic (WBN/kob) rats. Phytomedicine 2004;11:188-95.
37. Goto H, Shimada Y, Akechi Y, Kohta K, Hattori M, Terasawa K. Endothelium-dependent vasodilator effect of extract prepared from the roots of Paeonia lactiflora on isolated rat aorta. Planta Med 1996;62:436-9.
38. Tanikawa K, Goto H, Nakamura N, Tanaka N, Hattori M, Itoh T, et al. Endothelium-dependent vasodilator effect of tannin extract from Cinnamonomi Cortex on isolated rat aorta. J Trad Med 1999;16:45-50.
39. van Dinther-Janssen AC, Horst E, Koopman G, Newmann W, Scheper RJ, Meijer CJ, et al. The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol 1991;147:4207-10.
40. Kitani A, Nakashima N, Izumihara T, Inagaki M, Baoui X, Yu S, et al. Soluble VCAM-1 induces chemotaxis of jurkat and synovial fluid T cells bearing high affinity very late antigen-4. J Immunol 1998;161:4931-8.